同步乳腺癌评估过程中发现的额外钙化的恶性阳性预测值
回顾性纳入2018年1月1日至2022年12月31日连续103例乳腺癌患者 pretreatment 评估中发现的113簇额外钙化,由3名乳腺影像专科医师共识评估形态、分布及BI-RADS分类。41%钙化簇活检为恶性,排除未手术的非典型增生后50.5%最终为恶性;BI-RADS 3至5的恶性阳性预测值分别为20.7%、40.7%、63%、85.7%和100%。多因素分析显示指数肿瘤多灶/中央性、BI-RADS分类及钙化位于同侧距癌<35 mm为恶性独立预测因素;作者结论认为额外钙化恶性概率高于筛查人群,即使呈可能良性(BI-RADS 3)特征也需活检。
要点
- 额外钙化总体恶性比例高:活检恶性41%,排除未手术非典型增生后最终恶性50.5%。
- BI-RADS 3、4a、4B、4c、5的恶性阳性预测值分别为20.7%、40.7%、63%、85.7%和100%。
- 同侧距指数癌<35 mm、BI-RADS分类及指数肿瘤多灶/中央性为恶性独立预测因素。
核心结论
- 乳腺癌 pretreatment 评估中发现的额外钙化恶性概率高于筛查人群,即使呈可能良性(BI-RADS 3)特征也需活检。
研究设计与样本
- 回顾性研究,经机构审查委员会批准并豁免知情同意,连续纳入2018年1月1日至2022年12月31日本中心103例乳腺癌患者 pretreatment 评估中发现的113簇额外钙化。
- 由3名乳腺影像专科医师共识评估钙化形态、分布及BI-RADS分类,并收集侧别及与癌的距离。
- 按BI-RADS分类计算钙化恶性阳性预测值,采用非条件logistic回归进行单因素及多因素分析评估与恶性相关的因素。
关键影像表现/征象
- 额外钙化簇中41%活检为恶性、31%为良性、28%为非典型增生。
- 排除未手术的非典型增生后,50.5%额外钙化最终为恶性、49.5%为良性。
- 60%的钙化未在初始外院诊断评估中描述。
诊断标准与关键数值
- BI-RADS 3的恶性阳性预测值为20.7%。
- BI-RADS 4a的恶性阳性预测值为40.7%。
- BI-RADS 4B的恶性阳性预测值为63%。
- BI-RADS 4c的恶性阳性预测值为85.7%。
- BI-RADS 5的恶性阳性预测值为100%。
临床应用与阅片要点
- 阅片时对额外钙化需记录形态、分布、BI-RADS分类、侧别及与指数癌的距离。
- 额外钙化位于同侧距指数癌<35 mm、BI-RADS分类及指数肿瘤多灶/中央性为恶性独立预测因素。
- 初始外院诊断评估中60%的钙化未被描述,提示需仔细复核外院影像。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the positive predictive value and factors predictive of malignancy of additional calcifications in the pre-therapeutic work-up of a synchronous breast cancer.
MATERIALS AND METHODS: Institutional review board approval was obtained for this retrospective study and informed consent was waved. Consecutive patients referred to our center between January 1st 2018 and December 31st 2022 for a breast cancer and who presented additional calcifications detected during the pretreatment work-up were eligible for inclusion in this study. Morphology, distribution and BI-RADS category of the calcifications were assessed in consensus by 3 radiologists specialized in breast imaging. Side and distance from the cancer were collected. The predictive value of malignancy of the calcifications was calculated for each BI-RADS category. Factors associated with malignancy were evaluated by logistic non-conditional regression on univariate and multivariate analysis.
RESULTS: One hundred and thirteen clusters of calcifications in 103 patients were included. Among the groups of calcifications 41 % were malignant, 31 % benign and 28 % were atypia on biopsy. After exclusion of the non-operated atypia, 50.5 % of additional calcifications were ultimately malignant and 49.5 % were benign. The predictive value of malignancy was 20.7 %; 40.7 %; 63 %; 85.7 % and 100 % for category BI-RADS 3, 4a, 4B, 4c and 5 respectively. On multivariate analysis, multifocality or centricity of the index tumour (P = 0.01), BI-RADS classifications (P = 0.0001) and location ipsilateral less than 35 mm to the index cancer (P = 0.008) of the additional calcifications were found to be independent predictors of malignancy. Sixty percent of calcifications were not described on the initial out-center diagnostic work-up.
CONCLUSION: Additional calcifications detected during the pretreatment work-up of a breast cancer are associated with a higher probability of malignancy than in a screening population and require biopsy even when demonstrating probably benign (BI-RADS 3) features.
引用
- Vidaud A, Deleau F, Cantarel C, et al. Positive predictive value of malignancy for additional calcifications found during evaluation of a synchronous breast cancer. Eur J Radiol. 2024. PMID: 39447424. doi:10.1016/j.ejrad.2024.111794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。